tbuckley/cabot-search huggingface dataset:
Unusual Epidemic of Methemoglobinemia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Microenvironment-driven sequential ferroptosis, photodynamic therapy, and chemotherapy for targeted breast cancer therapy by a cancer-cell-membrane-coated nanoscale metal-organic framework
Authors: Wei-Lun Pan, Yong Tan, Wei Meng, Nai-Han Huang, Yi-Bang Zhao, Zhi-Qiang Yu, Zhong Huang, Wen-Hua Zhang, Bin Sun, Jin-Xiang Chen
Journal: Biomaterials (2022)
Whither Type 1 Diabetes?
Authors: Domenico Accili
Journal: New England Journal of Medicine (2020)

Since 1922, insulin has been the sole effective treatment for type 1 diabetes, which is now known to be the result of T-cell–mediated autoimmune destruction of pancreatic beta cells.1 In 1982, the approval of synthetic recombinant human insulin by the Food and Drug Administration heralded an era of nimbler pharmacokinetics and delivery devices that yielded better outcomes. Yet, insulin-based treatments are increasingly complex, costly, and limited by the risk of hypoglycemia. Three potentially complementary approaches are vying to become the standard of care for type 1 diabetes in the 21st century; these approaches include automated devices to deliver insulin (with . . .
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
Authors: Rami S. Komrokji, Uwe Platzbecker, Pierre Fenaux, Amer M. Zeidan, Guillermo Garcia-Manero, Ghulam J. Mufti, Valeria Santini, María Díez-Campelo, Carlo Finelli, Joseph G. Jurcic, Peter L. Greenberg, Mikkael A. Sekeres, Amy E. DeZern, Michael R. Savona, Jeevan K. Shetty, Rodrigo Ito, George Zhang, Xianwei Ha, Jay T. Backstrom, Amit Verma
Journal: Leukemia (2022)

Myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a myeloid disorder with myelodysplastic and myeloproliferative features [1,2].MDS/MPN-RS-T-associated anemia causes fatigue, reduced quality of life, and worse survival [3][4][5].Patients with MDS/MPN-RS-T have favorable overall survival compared to patients with MDS-RS [6]; however, ~50% of patients require red blood cell (RBC) transfusions resulting in protracted transfusion dependence.Patients with MDS/MPN-RS-T also have a fourfold higher thrombotic event risk compared to patients with MDS with ring sideroblasts (MDS-RS) [7].Treatment of MDS/MPN-RS-T aims to improve anemia, reduce thrombotic event risk, lower platelets, and/or modify the disease course [6,8].However, data supporting the efficacy of these treatments are scarce.Luspatercept is a first-in-class erythroid maturation agent that binds several transforming growth factor-β superfamily ligands, enhancing late-stage erythropoiesis [9].The results of the phase 3 MEDALIST study (NCT02631070) [10] led to its approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of anemia in adults with lower-risk MDS-RS or MDS/MPN-RS-T requiring ≥2 RBC units/8 weeks after erythropoiesisstimulating agent (ESA) failure [11].Here, we report a post hoc analysis of luspatercept efficacy and safety in patients with MDS/ MPN-RS-T from the MEDALIST study.The MEDALIST study enrolled 229 adults with lower-risk MDS-RS who required ≥2 RBC units/ 8 weeks and were refractory or intolerant to ESAs [10].Patients were randomized 2:1 to luspatercept or placebo, administered subcutaneously every 3 weeks for 24 weeks.Luspatercept starting dose was 1.0 mg/kg, with titration to a maximum of 1.75 mg/kg, according to
Vestnik Khirurgii Grekova, Leningrad
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of Contents
Authors: Nima Alamdari, Zaira Aversa, Estibaliz Castillero, Per-Olof Hasselgren, Microrna Regulation, Lipid Metabolism, Elena Flowers, Erika Froelicher, Bradley Aouizerat, Panagiotis Anagnostis, Niki Katsiki, Fotini Adamidou, Vasilios Athyros, Asterios Karagiannis, Marina Kita, Dimitri Mikhailidis
Journal: Metabolism (2012)
Cooperative coordination-mediated multi-component self-assembly of “all-in-one” nanospike theranostic nano-platform for MRI-guided synergistic therapy against breast cancer
Authors: Xiaojie Chen, Xudong Fan, Yue Zhang, Yinghui Wei, Hangsheng Zheng, Dandan Bao, Hengwu Xu, Ji-Gang Piao, Fanzhu Li, Hongyue Zheng
Journal: Acta Pharmaceutica Sinica B (2022)

Carrier-free multi-component self-assembled nano-systems have attracted widespread attention owing to their easy preparation, high drug-loading efficiency, and excellent therapeutic efficacy. Herein, MnAs-ICG nanospike was generated by self-assembly of indocyanine green (ICG), manganese ions (Mn2+), and arsenate (AsO43-) based on electrostatic and coordination interactions, effectively integrating the bimodal imaging ability of magnetic resonance imaging (MRI) and fluorescence (FL) imaging-guided synergistic therapy of photothermal/chemo/chemodynamic therapy within an "all-in-one" theranostic nano-platform. The as-prepared MnAs-ICG nanospike had a uniform size, well-defined nanospike morphology, and impressive loading capacities. The MnAs-ICG nanospike exhibited sensitive responsiveness to the acidic tumor microenvironment with morphological transformation and dimensional variability, enabling deep penetration into tumor tissue and on-demand release of functional therapeutic components. In vitro and in vivo results revealed that MnAs-ICG nanospike showed synergistic tumor-killing effect, prolonged blood circulation and increased tumor accumulation compared to their individual components, effectively resulting in synergistic therapy of photothermal/chemo/chemodynamic therapy with excellent anti-tumor effect. Taken together, this new strategy might hold great promise for rationally engineering multifunctional theranostic nano-platforms for breast cancer treatment.
Metal ions-bridged J-aggregation mediated nanoassembly composition for breast cancer phototherapy
Authors: Chen Chen, Shan Yang, Yufei Liu, Yue Qiu, Jing Yao
Journal: Asian Journal of Pharmaceutical Sciences (2022)

Recently, the highly ordered J-aggregates of organic dyes with intriguing optical properties have received considerable attention in biomedical applications. Herein, binary metal ions Mn(II)/Fe(III) are used to induce the formation of indocyanine green (ICG) J-aggregates. Further, the sheet-like J-aggregates are able to act as "carriers" for loading hydrophobic chemotherapeutic gambogic acid (GA), realizing the effect of "killing two birds with one stone" for both treatment and delivery. The as-designed nanoassembly is formed spontaneously in aqueous environment via π-π stacking, electrostatic interaction, and hydrophobic force, exhibiting enhanced photostability of ICG and outstanding reactive oxygen species (ROS) generation ability. Moreover, significant inhibition of tumor growth by the synergetic effect of phototherapy and chemotherapy is verified in a subcutaneous 4T1 tumors model. In conclusion, this work not only presents a facile and green approach to manufacture carrier-free nanodrugs, but also establishes a universal platform that has potential application in the co-delivery of near-infrared dye and hydrophobic molecules.
Factor XI deficiency in a Bedouin family
Authors: Lev Hatskelzon, A. Dvilansky, Gershon Holcberg
Journal: American Journal of Hematology (1996)

To prevent heat illnesses, a high index of suspicion should be maintained during a heat wave or while using unacclimatized workers in heavy labor.Employers should measure wet bulb globe temperature index (which correlates with deep body temperature) and plan work schedules within permissible threshold limit values [ 3 ] .In this respect, the workers' compensation insurer can provide critical technical know-how to its insureds; this will reduce heat-related injuries and claim expense.We hypothesize that the observed thrombocytopenia and leukopenia were caused by thermolysis since they were noted on the first day of heat exhaustion and progressively improved.Circulating platelets and neutrophils have a relatively short life span of 10 days and 10 hours, respectively [4]; this may explain their prompt replenishment from bone marrow.Although thrombocytopenia (with disseminated intravascular coagulation) is often observed in heat stroke [1,5], this is the first report of this potentially serious complication in a mild heat illness.
HIV Antibody Screening
Authors: Ronald Bayer
Journal: JAMA (1986)

THE ACQUIRED immunodeficiency syndrome (AIDS) poses a compelling ethical challenge to medicine, science, public health, the legal system, and our political democracy. This report focuses on one aspect of that challenge: the use of blood tests to identify individuals who have been infected with the retrovirus human immunodeficiency virus (HIV). In this article we follow the terminology recently proposed by the International Committee on the Taxonomy of Viruses; that is, we use the term<i>human immunodeficiency virus</i>. This replaces the more cumbersome dual terminology of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/ LAV). The issue is urgent the tests are already in use and plans to implement them much more broadly are being proposed.<sup>1</sup>The issue is also complex: at stake is a potential conflict between the community's interests in stopping the spread of a devastating disease and in preserving important values of individual liberty and equal rights.
Adolescent enuresis. A multiple contingency hypothesis
Authors: S. Murphy
Journal: JAMA (1971)

Nocturnal enuresis, or wetting of the bed, is a condition which has been known for centuries. The array of theories regarding its etiology and cure is overwhelming, as is the volume of papers written on the subject. In spite of this, very little of a definite nature is known. The confusion stems from the publication of positive findings by investigators in quite different fields which are not readily reconciled. Enuresis has been said to be due to delayed or immature development, and parents are frequently reassured that if enuresis has not stopped before, puberty will surely bring an end to wet beds. But, neurological investigations often report epileptiform or slow brain waves among enuretics, while urologists find local urological abnormalities. The psychiatrist tells us the enuretic is a disturbed child, while the socially oriented investigator blames the family and its poor adjustment. The present study represents an attempt to sort
Preconception Care
Authors: Brian W. Jack
Journal: JAMA (1990)

THE BIRTH of a healthy baby to a healthy woman and family depends, in part, on a woman's general health and well-being before conception as well as on the amount and quality of prenatal care. Health care before pregnancy can ameliorate disease, improve risk status, and help prepare a family for childbearing. Some interventions that are available prior to conception are not possible once a woman conceives. The trend among women who are in middle- and upper-income levels to delay pregnancy until they are 30 years of age or older has led to increased consumer demand for assistance in preparation for pregnancy. In recent years, the idea has emerged of an organized, comprehensive program that identifies and reduces women's reproductive risks before conception. This concept has been called "preconception care."<sup>1</sup> Development of this concept has been identified as a priority for the 1990s.<sup>2</sup>The Institute of Medicine's<i>Preventing</i>
Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors
Authors: Yang Du, Ye Liu, Di Wang, Hua Bai, Zhijie Wang, Xiran He, Pei Zhang, Jie Tian, Jie Wang
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background With the rapid development of immune checkpoint inhibitors and neoantigen (NeoV)-based personalized tumor vaccines, tumor immunotherapy has shown promising therapeutic results. However, the limited efficacy of available tumor vaccines impedes the development of personalized tumor immunotherapy. In this study, we developed a novel tumor vaccine system and proposed combined therapeutic strategies for improving treatment effects. Methods We developed a novel tumor vaccine system comprising a newly synthesized peptidic microarchitecture (PMA) with high assembly efficacy. The PMA-trapped neoantigen vaccine was developed to codeliver tumor neoantigen and the Toll-like receptor 9 agonist CpG (NeoV), abbreviated as PMA-NeoV. A microfluidic chip was used to produce PMA particles in a uniform and precise manner. Vaccine effectiveness was investigated both in vitro and in vivo. The combined immunotherapeutic effect of PMA-NeoV with anti-programmed cell death ligand 1 antibody (aPD-L1) or with the phosphatidylinositol 3‑kinase γ (PI3Kγ) inhibitor IPI-549 was further tested in MC38 mouse tumor model. Results PMA-NeoV not only promoted codelivery of the tumor vaccine but also potentiated vaccine immunogenicity. Moreover, compared with free NeoV, PMA-NeoV significantly increased the number of tumor-infiltrating lymphocytes, promoted the neoantigen-specific systemic immune response, and suppressed murine colon MC38 tumor growth. Furthermore, PMA-NeoV increased the expression of programmed cell death receptor-1 on T lymphocytes, and in combination with aPD-L1 eradicated seven of eight MC38 tumors by rescuing exhausted T lymphocytes. Moreover, we combined the PMA-NeoV with the IPI-549, a molecular switch that controls immune suppression, and found that this combination significantly suppressed tumor growth and eradicated five of eight inoculated tumors, by switching suppressive macrophages to their active state and activating T cells to prime a robust tumor immune microenvironment. Conclusions We developed a tumor vaccine delivery system and presented a promising personalized tumor vaccine-based therapeutic regimen in which a tumor vaccine delivery system is combined with an aPD-L1 or PI3Kγ inhibitor to improve tumor immunotherapy outcomes.
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1961)

WILLIAM A. R. CHAPIN, M.D., 1890–1961Seventy-one years to the day — March 15 — when W. A. R. Chapin was born in an upstairs bedroom in West Springfield, the first and only son of a locomotive engineer, he succumbed to the ravages of a malignant invader. He must have sensed that time was running out, for he told us at his final meeting with fellows of the Hampden District that he wished everyone to know that whatever he had done in the past that had offended anyone, at times perhaps impulsively, was never prompted by self-advancement.We know from . . .
Shall The Journal be Removed to Washington?
Authors: F. S. Thomas
Journal: JAMA (1891)

<h3>THE ACTION OF THE MEDICAL SOCIETY OF THE MISSOURI VALLEY.</h3> The following resolution was unanimously passed by the Medical Society of the Missouri Valley, in session at Omaha, Neb., March 20: Whereas, It having come to the knowledge of this Society that an effort is being made to remove the headquarters ofThe Journal of the American Medical Associationfrom its present location in Chicago to Washington, D. C.; Therefore, be it <i>Resolved</i>, That we, the Medical Society of the Missouri Valley, instruct our delegates to the coming meeting of the American Medical Association to use all honorable means to retain the headquarters of said Journal in its present location. Council Bluffs, Iowa, March 21, 1891.
ADAPTATION OF THE SINCLAIR SKATE TO THE THOMAS HIGH-BRIDGE SPLINT
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrections
Journal: BMJ (1966)

Bleeding from oesophageal varices can usually be controlled by medical means.'If bleeding persists, and surgery seems needed, the patient is probably in liver failure, which is causing the bleeding in addition to the portal hypertension.The simplest way to stop the bleeding is by intravenous pitressin, 20 ml.intravenously in 100 ml.5%1.glucose, given over 10 minutes.This can be given in the most primitive conditions provided a refrigerator is available to store pitressin.It is rapidly inactivated with heat.The pitressin lowers the portal blood pressure.Trans- fusion, of course, is also necessary.Once the patient has stopped bleeding the question of surgery arises, particularly porta- caval anastomosis.If the patient is not in liver failure (no jaundice, coma, or ascites) this operation may be relevant.The patient must be transferred to a specialist centre for it.
Marriages
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quick Stats: Percentage of Children and Adolescents Aged 5–17 Years with Diagnosed Attention-Deficit/Hyperactivity Disorder (ADHD),* by Race and Hispanic Ethnicity — National Health Interview Survey,United States, 1997–2014
Authors: Holly Hill, Laurie Elam-Evans, David Yankey, James Singleton, Maureen Kolasa, Thomas Frieden, Harold Jaffe, Joanne Cono, Chesley Richards, Michael Iademarco, Sonja Rasmussen, Charlotte Kent, Jacqueline Gindler, Acting Editor, Teresa Rutledge, Douglas Weatherwax, Teresa Hood, Jude Rutledge, Martha Boyd, Maureen Leahy, Julia Martinroe, Stephen Spriggs, Brian Wood, Quang Doan, Phyllis King, Teresa Moreland, Terraye Starr, Timothy Jones, Matthew Boulton, Ann Arbor, Virginia Mi, Jonathan Caine, Los Fielding, David Angeles, William Fleming, King Halperin, Rima Khabbaz, Patricia Quinlisk, Patrick Remington, William Roper, William Schaffner, Natalia Melnikova, Gale Burstein
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

The reduction in morbidity and mortality associated with vaccine-preventable diseases in the United States has been described as one of the 10 greatest public health achievements of the first decade of the 21st century (1).A recent analysis concluded that routine childhood vaccination will prevent 322 million cases of disease and about 732,000 early deaths among children born during 1994-2013, for a net societal cost savings of $1.38 trillion (2).The National Immunization Survey (NIS) has monitored vaccination coverage among U.S. children aged 19-35 months since 1994 (3).This report presents national, regional, state, and selected local area vaccination coverage estimates for children born from January 2011 through May 2013, based on data from the 2014 NIS.For most vaccinations, there was no significant change in coverage between 2013 and 2014.The exception was hepatitis A vaccine (HepA), for which increases were observed in coverage with both ≥1 and ≥2 doses.As in previous years, <1% of children received no vaccinations.National coverage estimates indicate that the Healthy People 2020 target* of 90% was met for ≥3 doses of poliovirus vaccine (93.3%), ≥1 dose of measles, mumps, and rubella vaccine (MMR) (91.5%), ≥3 doses of hepatitis B vaccine (HepB) (91.6%), and ≥1 dose of varicella vaccine (91.0%).Coverage was below target for ≥4 doses of diphtheria, tetanus, and acellular pertussis vaccine (DTaP), the full series of Haemophilus influenzae type b (Hib) vaccine, hepatitis B (HepB) birth dose, † ≥4 doses pneumococcal conjugate vaccine (PCV), ≥2 doses of HepA, the full series of rotavirus vaccine, and the combined vaccine series.§ Examination of coverage by child's race/ethnicity revealed lower estimated coverage among non-Hispanic black children compared with non-Hispanic white children for several vaccinations, including DTaP, the full series of Hib, PCV, rotavirus vaccine, and